Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data, presented at a medical meeting on Monday, for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).

The highest scoring names in small cap from 1 year ago (3/20/2013) returned 3,708 bps more than the S&P 500. The best performers have been RAD up 255%, CAMP up 205%, JAZZ up 163%, MDSO up 127%, GBX up 109%, and HOMB up 90%.

Covering the stocks to watch, and the top scoring stocks which should be on your buy list.

Our weekly best and worst reports show you stocks with the best potential returns over the coming 6 to 12 months. Those stocks appearing in our best list should be bought while those appearing in our worst list should be sold.

Our weekly best and worst reports show you stocks with the best potential returns over the coming 6 to 12 months.